Cargando…
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpo...
Autores principales: | Borlaug, Barry A., Kitzman, Dalane W., Davies, Melanie J., Rasmussen, Søren, Barros, Eric, Butler, Javed, Einfeldt, Mette Nygaard, Hovingh, G. Kees, Møller, Daniél Vega, Petrie, Mark C., Shah, Sanjiv J., Verma, Subodh, Abhayaratna, Walter, Ahmed, Fozia Z., Chopra, Vijay, Ezekowitz, Justin, Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Melenovsky, Vojtech, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, van der Meer, Peter, Von Lewinski, Dirk, Wolf, Dennis, Kosiborod, Mikhail N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504076/ https://www.ncbi.nlm.nih.gov/pubmed/37635157 http://dx.doi.org/10.1038/s41591-023-02526-x |
Ejemplares similares
-
Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022) -
Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022) -
Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021) -
New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022) -
Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)